Tactile Systems Technology (NASDAQ:TCMD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tactile Systems Technology (NASDAQ:TCMD) from a buy rating to a strong-buy rating in a report released on Saturday,Wall Street Zen reports.

Several other research firms have also commented on TCMD. BTIG Research reduced their price objective on shares of Tactile Systems Technology from $39.00 to $35.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Weiss Ratings upgraded shares of Tactile Systems Technology from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, October 13th. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.60.

Tactile Systems Technology Stock Performance

Shares of Tactile Systems Technology stock opened at $22.87 on Friday. The company has a market capitalization of $518.01 million, a PE ratio of 22.14 and a beta of 0.82. The company has a 50-day simple moving average of $22.72 and a two-hundred day simple moving average of $25.91. Tactile Systems Technology has a one year low of $15.32 and a one year high of $37.77.

Tactile Systems Technology (NASDAQ:TCMD) last released its quarterly earnings results on Monday, November 2nd. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. Tactile Systems Technology had a net margin of 7.10% and a return on equity of 11.49%. The business had revenue of $91.86 million during the quarter, compared to analyst estimates of $91.99 million. On average, equities analysts predict that Tactile Systems Technology will post 1.10 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tactile Systems Technology news, CEO Sheri Dodd sold 10,978 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $29.44, for a total value of $323,192.32. Following the completion of the sale, the chief executive officer owned 232,907 shares of the company’s stock, valued at approximately $6,856,782.08. This trade represents a 4.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Tactile Systems Technology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. USA Financial Formulas purchased a new position in Tactile Systems Technology in the 1st quarter worth $71,000. Summit Securities Group LLC acquired a new stake in Tactile Systems Technology during the 1st quarter worth about $75,000. Versant Capital Management Inc grew its stake in Tactile Systems Technology by 36.4% during the 2nd quarter. Versant Capital Management Inc now owns 3,285 shares of the company’s stock valued at $98,000 after purchasing an additional 876 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Tactile Systems Technology during the 2nd quarter valued at about $101,000. Finally, IFP Advisors Inc grew its stake in Tactile Systems Technology by 24.3% during the 2nd quarter. IFP Advisors Inc now owns 3,606 shares of the company’s stock valued at $107,000 after purchasing an additional 704 shares during the last quarter. 83.43% of the stock is owned by hedge funds and other institutional investors.

Tactile Systems Technology News Summary

Here are the key news stories impacting Tactile Systems Technology this week:

• Positive Sentiment: Adjusted earnings were $0.31 per share, exceeding the $0.28–$0.30 analyst consensus. Lymphedema revenue continued to grow at a double-digit rate, providing the company’s main growth engine. Tactile Systems Technology Q3 earnings article
• Positive Sentiment: Management’s earnings call highlighted continued momentum in the lymphedema market, which is partially offsetting weakness in the company’s smaller airway-clearance product line. Q3 2026 earnings call transcript
• Neutral Sentiment: Wall Street Zen upgraded its rating on TCMD, a favorable technical or analyst signal, although the upgrade is unlikely to outweigh the company’s operating results. TCMD rating upgrade article
• Negative Sentiment: Quarterly revenue of $91.86 million was slightly below the $91.99 million consensus, while EPS declined from $0.36 a year earlier. Tactile Medical third-quarter results
• Negative Sentiment: Higher sales and administrative expenses reduced operating income, and an expanding AffloVest inventory problem adds risk to near-term results. Airway-clearance sales also contracted, making growth increasingly dependent on lymphedema products. AffloVest inventory and lymphedema growth article

About Tactile Systems Technology

Tactile Systems Technology, doing business as Tactile Medical, develops and provides medical devices and services for people with chronic swelling and related conditions. The company focuses primarily on lymphedema and chronic venous insufficiency, conditions that can cause persistent fluid buildup in the limbs and trunk.

Its principal products include advanced pneumatic compression devices, such as the Flexitouch Plus system for the treatment of lymphedema and the Entre Plus system for home treatment of lymphedema and chronic venous insufficiency.